# Gliknik

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gliknik

- Industry: Biotechnology
- Headquarters: Baltimore, US
- Website: www.gliknik.com
- Total disclosed funding: $21M
- Latest round: Series C (Jun 24, 2021)
- Investors on record: 4

## About

Gliknik Inc. is a US-based biotechnology company focused on the development of innovative biologic therapies designed to treat immune disorders, specifically autoimmune diseases and certain cancers.Founded in 2007 and headquartered in Baltimore, US, Gliknik Inc. specializes in developing biologics for immune disorders. The company has successfully closed 11 deals, with its most recent funding round occurring on June 29, 2023, raising USD 5.38 mn. David Block serves as the CEO of the company.Gliknik Inc. specializes in the discovery and development of innovative biologics aimed at treating immune disorders, particularly autoimmune diseases and certain cancers. The company’s core product offerings include GL-2045 and GL-0719, both of which are recombinant Fc fusion proteins currently in clinical trials. GL-2045 is designed to mimic the effects of intravenous immunoglobulin (IVIG) in treating autoimmune diseases, which is approved for various conditions and has a significant market presence, generating approximately USD 12 bn annually. GL-0719 selectively inhibits the classical and lectin complement pathways to treat autoimmune diseases associated with their over-activation. Together, these products target a wide range of end-users, including patients suffering from conditions like chronic inflammatory demyelinating polyneuropathy (CIDP) and other autoimmune diseases. Gliknik's products are primarily marketed in North America and Europe, where they aim to provide effective treatment alternatives in the evolving landscape of immune disorder therapies.Gliknik’s revenue model is anchored in the successful progression of its clinical assets, particularly GL-2045 and GL-0719. The company engages in business-to-business transactions with healthcare providers and pharmaceutical partners, deriving revenue from clinical trial funding, potential licensing agreements, and future product commercialization. As these biologics advance through clinical trials, Gliknik could enter into partnerships with larger pharmaceutical companies for development and distribution, significantly affecting its revenue streams. The company’s flagship products, GL-2045 and GL-0719, will play a pivotal role once they gain regulatory approval and enter the market, opening avenues for various pricing models based on market demand and competitive analysis within the autoimmune disease treatment landscape.In June 2023, Gliknik Inc. raised USD 5.38 mn in venture funding aimed at supporting the advancement of its clinical assets and the development of new products. The company plans to continue the clinical trials for GL-2045 and GL-0719, with expectations for potential market release following successful trials. Additionally, Gliknik aims to expand its market presence in Europe and North America, targeting new partnerships with pharmaceutical companies by the end of 2024 to enhance its distribution and commercialization capabilities.

## Funding rounds

- Series C, Jun 24, 2021, $12M — First In Capital, SAISO Partners
- Series C, May 20, 2021, $4.3M — First In Capital, SAISO Partners
- Series B, Oct 8, 2012, $4.9M — Baxter Ventures, LifeTech Development Partners

## Investors

- Baxter Ventures (https://capitalatlas.ai/funds/baxter-ventures) — Series B
- LifeTech Development Partners — Series B
- First In Capital (https://capitalatlas.ai/funds/first-in-capital) — Series C
- SAISO Partners — Series C